Purpose of review The pathophysiology of aspirin-exacerbated respiratory disease (AERD) is not fully understood and diagnostic methods and so far, treatments for AERD have not been standardized. We summarize recent research into the pathological mechanisms of AERD, diagnostic methods, and treatments for AERD patients.
INTRODUCTION
Aspirin-exacerbated respiratory disease (AERD) is a major clinical phenotype of NSAID hypersensitivity that involves upper and lower airway mucosa [1 && ]. Several studies demonstrated that AERD affects 7-20% of asthmatic patients [2, 3] . AERD is characterized by Samter's triad that includes asthma, chronic rhinosinusitis, and nasal polyps, which are exacerbated upon ingestion of cyclooxygenase (COX)-1 inhibitors such as aspirin and nonselective NSAIDs [4] . Patients with AERD typically have a higher prevalence of severe asthma phenotype with a requirement for high-dose corticosteroids compared with those with aspirin-tolerant asthma (ATA) [5] . Although the pathogenic mechanisms of AERD are not fully understood, numerous studies provided insight into AERD pathophysiology, which includes dysregulated eicosanoid metabolism, activated effector cells such as eosinophils, mast cells, and platelets. In addition, various genetic predispositions in AERD have also been found and offer information for personalized management of AERD patients. Presently, AERD diagnosis is mainly based on aspirin challenges; however, biomarkers for increased diagnostic and prognostic values have also been investigated. The safety and effectiveness of aspirin desensitization in AERD patients have also been investigated providing promising methods for the management of refractory AERD. Furthermore, some existing and novel biologics may offer promising treatment options for AERD. This review summarizes recent insights into the pathophysiology, diagnostic methods, and advances in AERD management.
The most well known underlying pathomechanism of AERD is the dysregulation of arachidonic acid metabolism [6] . COX inhibitors that shift arachidonic acid metabolism from COX to 5-lipoxygenase (5-LO) pathway are known to increase the production of cysteinyl leukotrienes (CysLTs), producing bronchoconstriction and airway inflammation [7,8 & ] . However, this cannot fully explain why COX inhibitors do not induce symptoms in ATA despite similar acting mechanisms. Recent evidence suggests different expression levels of metabolic enzymes and eicosanoids in the two arachidonic acid metabolism pathways between AERD and ATA patients [4] .
In COX pathway, arachidonic acid is converted into prostaglandins (PG) E 2 , PGF 2 , PGI 2 , and PGD 2 by corresponding prostaglandin synthases or into thromboxane (TBX) A 2 by TBX synthase. Among the prostaglandins, PGD 2 can induce bronchoconstriction, vasodilation and recruit eosinophils, basophils, and T-helper cells by interaction with its receptor D prostanoid 2 or the G-protein-coupled chemokine receptor homologous molecule expressed on Th2 lymphocytes (CRTH 2 ). AERD patients had an elevated PGD 2 generation that further increased in a subgroup of AERD patients intolerant to high-dose aspirin desensitization but decreased in the tolerant subgroup [9, 10] . In contrast, PGE 2 has a protective effect against bronchoconstriction, allergic inflammation, mast cell degranulation, and eosinophil recruitment when binding to its receptor, termed E prostanoid 2 (EP 2 ) [11] [12] [13] . Lower PGE 2 expressions in peripheral blood leukocytes, nasal epithelial cells, and nasal fibroblasts (NF) of AERD compared with ATA patients were reported [14 && ,15] . Additionally, reduced EP 2 expression was observed in nasal polyps and NF of AERD patients [9, 16] . The activation of EP 2 by PGE 2 or EP 2 agonists induces the accumulation of cyclic AMP (cAMP), which subsequently activates protein kinase A (PKA) to phosphorylate 5-LO and prevents the production of CysLTs [17, 18 && ]. In AERD patients, a lower level of PGE 2 -induced cAMP accumulation was noted in NF compared with control study participants, consistent with the reduced EP 2 expression in those cells [16] . In contrast, another study demonstrated comparable levels of PGE 2 -induced cAMP accumulation and EP 2 expression in granulocytes of AERD and ATA patients as well as control study participants [18 && ]. The latter study identified PKA dysfunction in granulocytes as a mechanism of PGE 2 resistance found in AERD patients [18 && ]. These findings suggest that a downregulation of EP 2 as well as a malfunction of its signaling pathway may contribute to AERD pathogenesis. However, altered PGE 2 -EP 2 expression level can vary among cell types and should be further studied.
Leukotriene (LT) A 4 , produced from arachidonic acid via the 5-LO pathway, is unstable and rapidly converted into LTC 4 , and subsequently into LTD 4 and LTE 4 . CysLTs bind to CysLT type 1 receptor (CysLTR 1 ) and/or CysLTR 2 . CysLTR 1 expressions on inflammatory cells are upregulated in AERD patients compared with ATA patients [4] . Increased activity of 5-LO and LTC 4 synthase as well as increased production of LTE 4 and other CysLTs in AERD have also been widely reported [6, 15] . LTE 4 was found to bind weakly to CysLTR 1 and CysLTR 2 in vitro and in vivo; however, it could interact with ADP-reactive purinergic receptor (P2Y12) or Gprotein-coupled receptor 99 [4] . However, a recent study found that LTE 4 can fully activate CysLTR 1 on human mast cells (LAD-2), which may explain its potent proinflammatory activity observed in asthmatic patients [19 & ]. Lipoxins (LX) are produced by 15-LO pathway and have been found to inhibit CysLTs production and eosinophilic infiltration into the lung of mice with pulmonary inflammation [15] . An epimer of LXA 4 (15-epi-LXA 4 ) is also produced by COX-2, which is acetylated in the presence of aspirin [8 & ]. Several studies [20] [21] [22] demonstrated lower levels of LXA 4 in nasal lavage fluid (NLF) and 15-epi-LXA 4 (an epimer of LXA 2 ) in urine of AERD patients compared with those of ATA patients, suggesting a protective role of these metabolites in AERD pathogenesis.
KEY POINTS
AERD pathophysiology mainly involves dysregulation of the eicosanoid metabolism, where not only reduced expression of EP2 but also the dysfunction of its pathway may be involved.
Novel AERD-associated genetic (e.g., P2RY12, DPP10) and epigenetic polymorphisms have been found. AERD diagnosis can be established with aspirin challenges via oral, bronchial, or nasal routes; in addition, biomarkers such as eosinophilia, serum periostin, LTE 4 in EBC, and BAT are potential candidates.
Biologics including antibodies against IgE (omalizumab) and IL-5 (mepolizumab) as well as CRTH 2 antagonists may offer potential in future treatment of AERD.
Increased eosinophil infiltration, degranulated mast cells in tissues, and platelet activation have been characterized in AERD (Fig. 1) . A higher level of eosinophilic cationic protein (ECP) in NLF as well as an increased serum level of eosinophil-derived neurotoxin were also found in AERD patients compared with those with ATA, which supports the involvement of eosinophil activation in AERD pathophysiology [23, 24] . Increased IL-5 production was found in nasal polyp tissue of AERD patients inducing eosinophil infiltration and activation [25] . Aspirin has been found to directly induce a higher production of PGD 2 from the eosinophils of AERD compared with ATA patients and implicates eosinophil as another source of PGD 2 in AERD apart from mast cell [26] . Mast cell activation in AERD is evidenced by the release of histamine, tryptase, and PGD 2 in NLF. A recent study [7] found an elevated epithelial IL-33 expression in AERD patients, which is induced by LTE 4 to activate mast cells. The role of mast cells in AERD has been widely reported; however, basophil activation levels at baseline and after aspirin stimulation were not different between AERD and ATA patients [27, 28] . Recent studies [29, 30 && ] on the role of platelet activation in AERD have shown elevated expressions of P-selectin, CD63, and CD69 on platelets of AERD patients, which correlated with CysLTs overproduction and persistent airflow limitation. Adherence of platelets to leukocytes (e.g., eosinophils, neutrophils, and monocytes) mediated by P-selectin also facilitates leukocyte adhesion and transmigration into inflamed airway tissues that contribute to AERD pathogenesis [15, 29, 30 && ]. However, plasma markers of platelet activation remained unchanged during aspirin challenge suggesting that plasma markers do not reflect platelet activation within the airways [30 && ]. Although these findings suggest potential therapeutic options targeting platelet activation and their interaction with leukocytes, factors that enhance platelet activation in AERD remain to be elucidated.
Genetic mechanisms
Numerous studies have identified genetic singlenucleotide polymorphisms (SNPs) associated with AERD (Table 1) [8 & ]. SNPs in CysLTR 1 (À634 C>T, À475 A>C, À336 A>G) and CysLTR 2 (À189 T>C) are shown to associate with AERD and could influence gene transcriptional activity [31] [32] [33] . COX-2 À765 G>C SNP could also affect gene transcriptional activity and contribute to PGD 2 production in AERD patients [34] . AERD susceptibility is also associated with the SNPs on TBXA 2 receptor gene (TBXA2R À4684 C>T, 795 T>C) [35, 36] , PGE receptor (PTGER)2 (À616 C>G, À166 G>A), PTGER3 (À1709 T>A, rs7543182, rs959), PTGER4 (À1254 A>G) [37] [38] [39] Two SNPs on P2Y12 receptor gene (P2RY12 742 T>C and 18 C>T) have been found to be associated with increased ECP level in NLF and P2Y12 expression level on platelets of AERD patients [46] . Our group demonstrated the associations of the rs17048175 (TT genotype) in dipeptidyl peptidase 10 gene (DPP10) with AERD susceptibility as well as increased total serum IgE and serum DPP10 levels in asthmatic patients [47 & ]. The different DNA methylation levels of 490 loci found in 437 genes among AERD and ATA patients also suggest an involvement of epigenetic factors in AERD pathogenesis [48] . However, these studies need to be replicated and further investigations are required to assess the role of genetic/epigenetic factors in the disease pathomechanism.
DIAGNOSIS OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE
Thorough history taking is fundamental to diagnose AERD. Kowalski 
&&
] suggested a stepwise approach for a careful history taking and diagnostic work-up based on the new classification in the guidelines. Oral aspirin challenge (OAC) remains the gold standard for AERD diagnosis; however, other tests with a reduced risk of adverse reactions and increased diagnostic yield have been investigated. They include other routes of aspirin challenge (e.g., bronchial or nasal challenge), biomarkers such as fractional exhaled nitric oxide (FeNO), eosinophilia, serum periostin, urine LTE 4 level, and basophil activation test (BAT) to diagnose AERD.
Bronchial aspirin challenge (BAC) has become widespread because of its safety and a shorter duration compared with OAC. However, BAC may have a lower sensitivity and cannot replace OAC when patients only have upper airway symptoms [49] . A recent study suggested a combination of fall in peak expiratory flow within 4-11 h after BAC (late-phase reaction) and at least 20% fall in forced expiratory volume in 1 s (FEV1) to yield a sensitivity of 91% and a specificity of 100% for AERD diagnosis [50] . Additionally, when extrabronchial symptoms (cutaneous and nasal symptoms), late-phase reaction, and the fall in FEV1 were taken into account, the BAC sensitivity reached 94% compared with 80.5% when only using spirometry criteria [50] .
Nasal lysine-aspirin challenge is an alternative method, especially in patients with severe asthma because it seldom triggers a bronchial response [49] . A recent study [51] indicated 88% of patients had a positive nasal challenge and 12% of the remaining patients had positive responses following OAC.
OAC provides sensitivity up to 90% and is presently the most sensitive diagnostic test for AERD. The test usually starts with 20-30 mg of aspirin followed by a gradually increasing dose every 3 h until a cumulative dose of 1000 mg has been reached [52] . In a meta-analysis, the mean provocative dose of aspirin that triggered respiratory symptoms was 85. 8 . Diagnostic biomarkers are presently under investigation. As AERD mainly involves eosinophilic inflammation and the dysregulation of CysLTs, eosinophilia is a suggestive diagnostic marker in suspected AERD [57] . Although increased numbers of activated eosinophils in bronchial biopsies of AERD patients were documented [58] , some studies have reported an insignificant difference in blood and sputum eosinophil counts between AERD and ATA patients even though the values tended to be higher in the AERD group [23, 59] . In comparison with ATA patients, AERD patients had a higher serum periostin level, which is considered a predictor for eosinophilic airway inflammation [60 && ,61]. Serum periostin levels in AERD patients were significantly higher in patients with severe chronic rhinosinusitis (CRS) compared with those with less severe CRS [60 && ]. Urinary CysLTs and LTE 4 metabolites were significantly higher in AERD patients compared with ATA, which increased further after an aspirin challenge test and indicated that urine LTE4 metabolite can be a potential biomarker to diagnose AERD [59] . However , data of exhaled breath condensate (EBC) LTE 4 levels are inconsistent among studies [52, 62] . Following BAC, EBC-LTE 4 levels were more increased in AERD patients but not statistically different from patients with ATA [62] .
The value of BAT in AERD diagnosis has also been investigated. However, levels of basophil activation at baseline and after aspirin stimulation showed inconsistent results yielding a low sensitivity, ranging from 30 to 67% [27, 28] . Therefore, the diagnostic value of BAT and its protocol should be further studied to apply to AERD diagnosis.
Considering the heterogeneity of AERD, a recent study has classified 201 AERD patients into four subphenotypes (latent classes) using an advanced biostatistical analysis, which includes class 1, moderate asthma with intensive upper airway symptoms and blood eosinophilia (18.9% of patients); class 2, mild asthma, relatively controlled with low healthcare use (34.8% of patients); class 3, severe asthma, poorly controlled with severe exacerbation and airway obstruction (41.3% of patients); and class 4, poorly controlled asthma with frequent and severe exacerbation in female patients (5.0% of patients) [63 && ]. This novel classification may facilitate the diagnosis and precision medicine for AERD patients, although its practical approach needs to be further investigated in larger cohorts.
ASPIRIN-EXACERBATED RESPIRATORY DISEASE TREATMENT
Treatment for AERD patients includes pharmacological therapies and desensitization, and presently novel treatment options with biologics are being AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CYSLTR, cysteinyl leukotriene receptor; DPP10, dipeptidyl peptidase 10; FCER, Fc-epsilonreceptor; FEV1, forced expiratory volume in 1 s; HLA, human leukocyte antigen; HNMT, histamine N-methyltransferase; IL-5RA, IL-5 receptor a; ND, no data; PGD, prostaglandin; PTGER, prostaglandin E receptor; SEA, staphylococcal enterotoxin A; SNP, single-nucleotide polymorphism; TBXA2R, thromboxane A2 receptor.
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explored (Fig. 1) . Leukotriene modulators, including leukotriene receptor antagonists (LTRAs) and 5-LO inhibitors, are widely used in AERD treatment. Aspirin desensitization may be considered when patients are refractory to conventional medications or need aspirin/NSAID maintenance [64] . Furthermore, specific antibodies against IgE (omalizumab) and IL-5 (mepolizumab), as well as CRTH 2 antagonists have shown promising effects in patients with asthma and/or nasal polyps. LTRA (e.g., montelukast) and 5-LO inhibitor (e.g., zileuton) are being prescribed as mono or add-on therapy to standard treatment based on the pathogenesis of AERD. Consequently, LTRA is the most widely used drug in clinics for treatment modality [65 & ]. AERD patients treated with an LTRA or 5-LO inhibitor showed improvement in symptoms, lung function, quality of life, exacerbations, and less bronchodilator use [66, 67] . In addition, LTRA has a protective effect on nasal response during nasal lysine-aspirin challenge as well as asthmatic response during OAC in patients with AERD [68 && ]. The therapeutic effects of LTRAs and 5-LO inhibitors for CRS with nasal polyposis (CRSwNP), regardless the coexistence of asthma or AERD, were also established [69] .
Aspirin desensitization has shown therapeutic effectiveness in the treatment of AERD [70] . In a recent survey with 190 AERD patients, 85 out of 93 patients (91%) who had undergone desensitization found the therapy to be effective in symptom control, whereas smaller groups of patients had their symptoms improved by LTRAs (50%), 5-LO inhibitors (52%), or omalizumab (57%) [65 & ]. Another study [71] also reported that AERD patients who received 624 mg of aspirin once daily for 6 months showed improvements in nasal symptoms, asthma control scores, and decreased use of inhaled corticosteroids. In addition, desensitization was shown to significantly improve lung function and sinusitis as estimated by sinus computed tomography scan [72] . In AERD patients who had nasal polypectomy, desensitization could improve both nasal symptoms and nasal polyp scores, as well as the requirement for recurrent surgery [73 & ]. There is no standardized protocol for aspirin desensitization; however, maintenance aspirin dose of 650 mg twice daily for the first month and a lower dose of 325 mg twice daily, as symptom controlled, are recommended [68 && ]. Omalizumab has been investigated in the treatment of moderate-to-severe allergic asthma [74] . In a small randomized, double-blind, placebo-controlled study, omalizumab effectively improved upper and lower airway symptoms, quality of life, and nasal polyp score in asthma patients; 12 of the 24 study participants in this study were sensitive to aspirin [75] . Local IgE in airway tissue was considered to have a pathogenic role in the disease [76] . Moreover, several case reports testified of omalizumab's beneficial effects in AERD [64, 65 & ]. Hence, omalizumab could be an add-on treatment for AERD patients with CRSwNP, although more clinical trials should be conducted.
Mepolizumab had a beneficial effect in a small randomized double-blind study with 20 patients with CRSwNP that included five patients with aspirin intolerance [77] . In total, 60% of patients who received two single intravenous injections of mepolizumab (750 mg) with 28-day interval had improved nasal polyp score and polyp size. Moreover, blood eosinophil count, serum ECP, and serum IL-5Ra subunit levels also significantly decreased in the mepolizumab-treated group [77] . A phase 2 clinical trial (NCT01362244) reported the benefit of mepolizumab in reducing the need for surgery in patients with severe bilateral nasal polyp, including those with aspirin hypersensitivity. Although the effectiveness and safety of mepolizumab in AERD has not yet been systematically investigated, anti-IL-5 antibodies may offer a promising treatment option because of the crucial role of IL-5 and eosinophil in AERD pathophysiology.
Given the role of PGD 2 and its receptor CRTH 2 in the AERD pathophysiology, CRTH 2 antagonists could be another potential treatment option. A multiple dose, randomized, double-blind, placebocontrolled study with approximately 440 asthmatic patients demonstrated a beneficial effect of the CRTH 2 antagonist (OC000459) on lung function and incidence of exacerbation in patients with uncontrolled eosinophilic asthma. Nevertheless, effectiveness of CRTH 2 antagonist in AERD treatment needs to be established [78] .
In addition to pharmacological therapies, dietary factors may also influence AERD control status. A low-salicylate diet was reported to reduce AERD symptoms in 24 of 71 (34%) AERD patients in a survey-based study [65 & ]. In another prospective, crossover single-blind multicenter study with 30 AERD patients, a 6-week low-salicylate diet significantly improved the disease scores [79 & ]. These findings suggest that controlling the diet of AERD patients could be of additional benefit to the current management of the disease.
CONCLUSION
AERD is a major manifestation of NSAID hypersensitivity and usually associated with severe asthma and CRS. The pathophysiology of AERD is complicated and involves dysregulation of the arachidonic acid metabolism, activated eosinophils, mast cells, and platelets with genetic/epigenetic alternations. Aspirin challenges by different routes such as oral, bronchial, and nasal challenges are confirmative methods for AERD diagnosis; in addition, novel biomarkers for AERD such as serum periostin are under investigation to increase diagnostic value. In addition to standard pharmacological treatment and desensitization, specific antibodies against IgE (omalizumab) and IL-5 (mepolizumab), as well as CRTH 2 antagonists may offer future treatment options for AERD.
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